TRDA (STOCKS)
Entrada Therapeutics, Inc. Common Stock
$13.890000
+0.390000 (+2.89%)
Prev close: $13.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Dipal Doshi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $531.00M
- Employees
- 183
- P/E (TTM)
- -4.00
- P/B (TTM)
- 1.69
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $25.42M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $183.32M |
| Operating Expenses | $183.32M |
| Research and Development | $142.27M |
| Other Operating Expenses | $41.05M |
| Operating Income/Loss | -$157.90M |
| Income/Loss From Continuing Operations After Tax | -$143.75M |
| Income/Loss From Continuing Operations Before Tax | $25.42M |
| Income Tax Expense/Benefit | $924.00K |
| Income Tax Expense/Benefit, Current | $924.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$143.75M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$143.75M |
| Net Income/Loss Available To Common Stockholders, Basic | -$143.75M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.47 |
| Diluted Earnings Per Share | -$3.47 |
| Basic Average Shares | 41,371,486 |
| Diluted Average Shares | 41,371,486 |
| Assets | $377.38M |
| Current Assets | $306.25M |
| Cash | $295.70M |
| Other Current Assets | $10.55M |
| Noncurrent Assets | $71.13M |
| Fixed Assets | $7.31M |
| Other Non-current Assets | $63.81M |
| Liabilities | $71.25M |
| Current Liabilities | $24.45M |
| Accounts Payable | $2.29M |
| Wages | $8.05M |
| Other Current Liabilities | $14.12M |
| Noncurrent Liabilities | $46.79M |
| Equity | $306.13M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $306.13M |
| Liabilities And Equity | $377.38M |
| Net Cash Flow From Operating Activities | -$128.51M |
| Net Cash Flow From Operating Activities, Continuing | -$128.51M |
| Net Cash Flow From Investing Activities | $116.81M |
| Net Cash Flow From Investing Activities, Continuing | $116.81M |
| Net Cash Flow From Financing Activities | $887.00K |
| Net Cash Flow From Financing Activities, Continuing | $887.00K |
| Net Cash Flow | -$10.82M |
| Net Cash Flow, Continuing | -$10.82M |
| Comprehensive Income/Loss | -$143.06M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$143.06M |
| Other Comprehensive Income/Loss | $695.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $695.00K |